Dermata Therapeutics, Inc.
DRMAHealthcare|Biotechnology|US
$0.76
+0.00 (+0.28%)
DCF Value
$7.66
Tangible Book / Share
$0.87
Cash / Share
$1.10
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06090721 DMT310-009 Topical in the Treatment of Acne Vulgaris | Acne Vulgaris | P3 | Completed | 520 | RCT, Double-blind | DMT310, Placebo |
| NCT03003104 DMT210 Topical Gel in the Treatment of Acne Rosacea | Acne Rosacea | P2 | Completed | 107 | RCT, Double-blind | DMT210 Topical Gel 5% |
| NCT03536637 DMT310-001 Topical in the Treatment of Acne Vulgaris | Acne Vulgaris | P2 | Completed | 121 | RCT, Double-blind | DMT310, Hydrogen Peroxide, Placebo |
| NCT04106778 DMT310-003 Topical in the Treatment of Acne Vulgaris | Acne Vulgaris | P2 | Completed | 181 | RCT, Double-blind | DMT310, Placebo |
| NCT02949960 DMT210 Topical Gel in the Treatment of Atopic Dermatitis | Atopic Dermatitis | P2 | Completed | 19 | RCT, Double-blind | DMT210 Topical Gel, Vehicle Control |
| NCT05108025 DMT310-005 Topical in the Treatment of Acne Rosacea | Acne Rosacea | P2 | Unknown | 180 | RCT, Double-blind | Topical Powder, Placebo Topical Powder |